Patents by Inventor Daniel Pinto
Daniel Pinto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240164354Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: ApplicationFiled: January 26, 2024Publication date: May 23, 2024Applicant: Merus B.V.Inventors: Ton LOGTENBERG, Rui Daniel PINTO, Erwin HOUTZAGER
-
Publication number: 20240156072Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: ApplicationFiled: September 8, 2023Publication date: May 16, 2024Applicant: Merus N.V.Inventors: Ton LOGTENBERG, Mark THROSBY, Robert A. KRAMER, Rui Daniel PINTO, Cornelis A. DE KRUIF, Erwin HOUTZAGER
-
Patent number: 11925174Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: GrantFiled: January 11, 2018Date of Patent: March 12, 2024Assignee: Merus N.V.Inventors: Ton Logtenberg, Rui Daniel Pinto, Erwin Houtzager
-
Patent number: 11785924Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: GrantFiled: January 5, 2018Date of Patent: October 17, 2023Assignee: Merus N.V.Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. De Kruif, Erwin Houtzager
-
Patent number: 11237165Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is a common human, human-like, or humanized light chain. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: GrantFiled: July 18, 2017Date of Patent: February 1, 2022Assignee: Merus N.V.Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. de Kruif, Erwin Houtzager
-
Patent number: 10966411Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: GrantFiled: October 19, 2009Date of Patent: April 6, 2021Assignee: Merus N.V.Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. de Kruif, Erwin Houtzager
-
Publication number: 20200319181Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is a common human, human-like, or humanized light chain. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: ApplicationFiled: June 19, 2020Publication date: October 8, 2020Applicant: Merus N.V.Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. De Kruif, Erwin Houtzager
-
Patent number: 10605808Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is a common human, human-like, or humanized light chain. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: GrantFiled: April 27, 2016Date of Patent: March 31, 2020Assignee: Merus N.V.Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. Dekruif, Erwin Houtzager
-
Publication number: 20180142002Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: ApplicationFiled: January 5, 2018Publication date: May 24, 2018Applicant: Merus N.V.Inventors: Ton LOGTENBERG, Mark THROSBY, Robert A. KRAMER, Rui Daniel PINTO, Cornelis A. DE KRUIF, Erwin HOUTZAGER
-
Publication number: 20180142004Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: ApplicationFiled: January 11, 2018Publication date: May 24, 2018Applicant: Merus N.V.Inventors: Ton LOGTENBERG, Rui Daniel PINTO, Erwin HOUTZAGER
-
Publication number: 20180142003Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: ApplicationFiled: January 9, 2018Publication date: May 24, 2018Applicant: Merus N.V.Inventors: Ton LOGTENBERG, Mark THROSBY, Robert A. KRAMER, Rui Daniel PINTO, Cornelis A. DE KRUIF, Erwin HOUTZAGER
-
Patent number: 9951124Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: GrantFiled: January 25, 2013Date of Patent: April 24, 2018Assignee: MERUS N.V.Inventors: Ton Logtenberg, Rui Daniel Pinto, Erwin Houtzager
-
Patent number: 9944695Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: GrantFiled: April 30, 2014Date of Patent: April 17, 2018Assignee: Merus N.V.Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. De Kruif, Erwin Houtzager
-
Publication number: 20180031555Abstract: Described are combinations of specific binding proteins, such as immunoglobulins, that are designed to be true combinations, essentially all components of the combination being functional and compatible with each other. Further provided are methods for producing a composition comprising at least two different proteinaceous molecules comprising paired variable regions, the at least two proteinaceous molecules having different binding specificities, comprising paired variable regions, at least two proteinaceous molecules having different binding specificities, comprising contacting at least three different variable regions under conditions allowing for pairing of variable regions and harvesting essentially all proteinaceous molecules having binding specificities resulting from the pairing.Type: ApplicationFiled: July 18, 2017Publication date: February 1, 2018Applicant: Merus N.V.Inventors: Hendricus Renerus Hoogenboom, Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. de Kruif, Erwin Houtzager
-
Patent number: 9765133Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: GrantFiled: April 29, 2014Date of Patent: September 19, 2017Assignee: Merus N.V.Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. De Kruif, Erwin Houtzager
-
Publication number: 20160238600Abstract: Described are combinations of specific binding proteins, such as immunoglobulins, that are designed to be true combinations, essentially all components of the combination being functional and compatible with each other. Further provided are methods for producing a composition comprising at least two different proteinaceous molecules comprising paired variable regions, the at least two proteinaceous molecules having different binding specificities, comprising paired variable regions, at least two proteinaceous molecules having different binding specificities, comprising contacting at least three different variable regions under conditions allowing for pairing of variable regions and harvesting essentially all proteinaceous molecules having binding specificities resulting from the pairing.Type: ApplicationFiled: April 27, 2016Publication date: August 18, 2016Applicant: Merus B.V.Inventors: Hendricus Renerus Hoogenboom, Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. de Kruif, Erwin Houtzager
-
Publication number: 20140317766Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: ApplicationFiled: April 29, 2014Publication date: October 23, 2014Inventors: Ton LOGTENBERG, Mark THROSBY, Robert A. KRAMER, Rui Daniel PINTO, Cornelis A. DE KRUIF, Erwin HOUTZAGER
-
Publication number: 20140314755Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: ApplicationFiled: April 30, 2014Publication date: October 23, 2014Inventors: Ton LOGTENBERG, Mark THROSBY, Robert A. KRAMER, Rui Daniel PINTO, Cornelis A. DE KRUIF, Erwin HOUTZAGER
-
Patent number: 7882429Abstract: A computer-implemented method of processing an Extensible Markup Language (XML) document can include loading an execution plan into a virtual machine, wherein the execution plan represents an XML schema, and loading an XML document into the virtual machine. XML processing functions available within the virtual machine can be selectively invoked according to the execution plan, wherein the XML processing functions operate upon the XML document. An indication of whether the XML document is valid according to the XML processing functions can be output.Type: GrantFiled: June 5, 2007Date of Patent: February 1, 2011Assignee: International Business Machines CorporationInventors: Abraham Heifets, Margaret G. Kostoulas, Michelle Anastasia Leger, Moshe Morris Emanuel Matsa, Eric Perkins, Daniel Pinto de Mello e Silva
-
Publication number: 20100146647Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: ApplicationFiled: October 19, 2009Publication date: June 10, 2010Applicant: Merus B. V.Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. de Kruif, Erwin Houtzager